Preservative free artificial tear

PreclinicalSmall molecule

Preservative free artificial tear is one of 35 small molecule programs targeting Viral Conjunctivitis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Viral ConjunctivitisActive, not recruiting

CataractActive, not recruiting

Viral ConjunctivitisPhase 2/Phase 3

Active, not recruiting

CataractPreclinical

Active, not recruiting

Competition

Competitive Landscape

219 competitors in Cataract

#DrugCompanyPhaseTrials

Toradol

JJavelin Pharmaceuticals

Phase 3

4 2

ISV-305

Sun Pharmaceutical Industries Limited

Phase 3

2 3

KPI-121

KKala Pharmaceuticals, Inc.

Phase 3

1 4

OCS-01

QQuan Dong Nguyen

Phase 3

1 5

Zolymbus

AbbVie

Preclinical

—6

Neurontin

VViatris Specialty LLC

Preclinical

3 7

Kenalog

BBassett Healthcare

Preclinical

1 8

Bactroban

PPadagis LLC

Preclinical

1 9

Ceftin

PPhiladelphia Eye Associates

Preclinical

1 10

Xylocaine

MMEDRx USA, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Viral Conjunctivitis1 trial

Artificial Tears Versus Preservative Free Ketorolac Trometamol 0.45% for Acute Viral Conjunctivitis

Completed·FFundação Altino Ventura·Phase 2/3·NCT01799863·50 enrolled

Cataract1 trial

Impact of DED on the Accuracy of Preoperative Keratometry Values in the Calculation of IOL Power for Cataract Surgery.

Not yet recruiting·UUniversity Hospital Sestre Milosrdnice·N/A·NCT06989827·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Preservative free artificial tear. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Preservative free artificial tear compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Preservative free artificial tear. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital Sestre Milosrdnice company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity Hospital Sestre Milosrdnice

Preservative free artificial tear

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Viral Conjunctivitis1 trial

Cataract1 trial

References

Drug Info

Quick Facts

Related News